Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest (RELAX)
Primary Purpose
Cardiac Arrest With Successful Resuscitation, Hypothermia, Skeletal Muscle Relaxant Overdose
Status
Completed
Phase
Phase 3
Locations
Austria
Study Type
Interventional
Intervention
rocuronium
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Cardiac Arrest With Successful Resuscitation focused on measuring cardiac arrest, therapeutic hypothermia, skeletal muscle paralysis, shivering, serum drug levels, basal metabolism
Eligibility Criteria
Inclusion Criteria:
- all patients receiving mild therapeutic hypothermia after cardiac arrest
- cardiac arrest due to cardiopulmonary origin
Exclusion Criteria:
- patients younger than 18 years
- traumatic cardiac arrest
- cardiac arrest due to exsanguination, strangulation, smoke inhalation, drug overdose, electrocution, hanging or drowning
- known or clinically apparent pregnancy
- no treatment with mild therapeutic hypothermia because of an AND order
- terminal illness
- a body core temperature below 35°C at hospital admission
- known allergic reaction against rocuronium
- history of myasthenia gravis
- obvious intoxication
- ward of the state or prisoner
- known epileptic disease
- cardiac arrest >6 hours prior to hospital admission
Sites / Locations
- Medical University of Vienna, Department of Emergency Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Rocuronium
Placebo
Arm Description
Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
Outcomes
Primary Outcome Measures
Number of shivering episodes
Shivering episodes will be detected according to the Shivering Assessment Scale
Secondary Outcome Measures
Elapsed time to target temperature
Dissipated energy to reach the target temperature
Changes in basal metabolism due to shivering or elevated stress levels
Depth of relaxation
via train of four measurement
Changes in serum levels of midazolam, fentanyl and rocuronium
Number of necessary boli of rocuronium
In case of a shivering episode, a bolus of rocuronium will be administered (0,25mg/kg)
Full Information
NCT ID
NCT01719770
First Posted
July 6, 2011
Last Updated
April 30, 2015
Sponsor
Medical University of Vienna
1. Study Identification
Unique Protocol Identification Number
NCT01719770
Brief Title
Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest
Acronym
RELAX
Official Title
Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
April 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Mild hypothermia improves neurological outcome after cardiac arrest. Neuromuscular blockers are in use, together with analgesia and sedation, during the cooling process in many centers to prevent shivering. Since neuromuscular blockers are accused to be associated with various side effects causing serious harm and/or leading to prolong ICU stay. So economical use seems to be reasonable. Furthermore, the use of neuromuscular blockers may mask epileptic activity. Therefore, post hypoxic seizures might remain undetected.
Aim of this study is to investigate if a continuous application of neuromuscular blockers is necessary to prevent shivering and thereby avoid the counter regulation to achieve the target temperature as soon as possible in mild hypothermic therapy after cardiac arrest.
A single center (university hospital) study. Randomized, double blinded, double dummy study design. Eligible are all adult patients after successful resuscitation due to cardiac arrest of presumed cardiac origin.
All patients receiving mild therapeutic hypothermia after cardiac arrest of presumed cardiopulmonary origin will be included.
Patients <18 years, cardiac arrest >6 hours before admittance at the hospital, patients with known or clinically apparent pregnancy, patients who reach our hospital with a body temperature below 35°C, patients with known allergic reactions against rocuronium, patients with a history of myasthenia gravis, patients with obvious intoxication, wards of the state/prisoners and patients with known epileptic disease will be excluded.
Primary outcome:
Shivering episodes will be scored with the Shivering Assessment Scale.
Secondary outcome:
Total doses of rocuronium, time to target core temperature of 33°C, dissipated energy and total energy needed during the cooling period will be compared between the two groups.
Changes in basal metabolism and depth of relaxation will be ascertained. Furthermore, serum levels of midazolam, fentanyl, rocuronium and stress hormones will be measured.
Train-of-four will be performed to assess the depth of relaxation. Sedation will be monitored via bispectral index; measurement of metabolic activity will be evaluated using indirect calorimetry. Additionally, EEG will be performed to detect epileptiform activities. Blood will be drawn to measure levels of midazolam, fentanyl and rocuronium.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Arrest With Successful Resuscitation, Hypothermia, Skeletal Muscle Relaxant Overdose
Keywords
cardiac arrest, therapeutic hypothermia, skeletal muscle paralysis, shivering, serum drug levels, basal metabolism
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Rocuronium
Arm Type
Active Comparator
Arm Description
Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
Intervention Type
Drug
Intervention Name(s)
rocuronium
Other Intervention Name(s)
Esmeron
Intervention Description
continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
sodium-chloride
Intervention Description
continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
Primary Outcome Measure Information:
Title
Number of shivering episodes
Description
Shivering episodes will be detected according to the Shivering Assessment Scale
Time Frame
during cooling period (mild therapeutic hypothermia will be performed for 24 hours after cooling initiation, rewarming with 0,4°C per hour until a body core temperature of 36°C is reached); total time of approximately 31 hours
Secondary Outcome Measure Information:
Title
Elapsed time to target temperature
Time Frame
Time from starting the cooling procedure until target temperature is reached - approximately 4 hours after cooling initiation
Title
Dissipated energy to reach the target temperature
Time Frame
Time from starting the cooling procedure until target temperature is reached - approximately 4 hours after cooling initiation
Title
Changes in basal metabolism due to shivering or elevated stress levels
Time Frame
during the first 72 hours after cardiac arrest
Title
Depth of relaxation
Description
via train of four measurement
Time Frame
during cooling and rewarming period, which will be approximately 30 hours up to 48 hours after initiation of cooling
Title
Changes in serum levels of midazolam, fentanyl and rocuronium
Time Frame
within the first 48 hours of treatment
Title
Number of necessary boli of rocuronium
Description
In case of a shivering episode, a bolus of rocuronium will be administered (0,25mg/kg)
Time Frame
during colling period (mild therapeutic hypothermia will be performed for 24 hours after cooling initiation, rewarming with 0,4°C per hour until a body core temperature of 36°C is reached); total time of approximately 31 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
all patients receiving mild therapeutic hypothermia after cardiac arrest
cardiac arrest due to cardiopulmonary origin
Exclusion Criteria:
patients younger than 18 years
traumatic cardiac arrest
cardiac arrest due to exsanguination, strangulation, smoke inhalation, drug overdose, electrocution, hanging or drowning
known or clinically apparent pregnancy
no treatment with mild therapeutic hypothermia because of an AND order
terminal illness
a body core temperature below 35°C at hospital admission
known allergic reaction against rocuronium
history of myasthenia gravis
obvious intoxication
ward of the state or prisoner
known epileptic disease
cardiac arrest >6 hours prior to hospital admission
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heidrun Losert, MD
Organizational Affiliation
Medical University Vienna, Department of Emergency Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Vienna, Department of Emergency Medicine
City
Vienna
ZIP/Postal Code
1190
Country
Austria
12. IPD Sharing Statement
Learn more about this trial
Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest
We'll reach out to this number within 24 hrs